These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
90 related articles for article (PubMed ID: 16310931)
1. p53 protein transduction therapy: successful targeting and inhibition of the growth of the bladder cancer cells. Inoue M; Tomizawa K; Matsushita M; Lu YF; Yokoyama T; Yanai H; Takashima A; Kumon H; Matsui H Eur Urol; 2006 Jan; 49(1):161-8. PubMed ID: 16310931 [TBL] [Abstract][Full Text] [Related]
2. Cell-penetrating D-isomer peptides of p53 C-terminus: long-term inhibitory effect on the growth of bladder cancer. Araki D; Takayama K; Inoue M; Watanabe T; Kumon H; Futaki S; Matsui H; Tomizawa K Urology; 2010 Apr; 75(4):813-9. PubMed ID: 19963248 [TBL] [Abstract][Full Text] [Related]
3. Restoration of p53 function in anaplastic Wilms' tumor. Delatte SJ; Hazen-Martin DJ; Re GG; Kelly JR; Sutphin A; Tagge EP J Pediatr Surg; 2001 Jan; 36(1):43-50. PubMed ID: 11150436 [TBL] [Abstract][Full Text] [Related]
4. In vitro efficacy of Fas ligand gene therapy for the treatment of bladder cancer. Sudarshan S; Holman DH; Hyer ML; Voelkel-Johnson C; Dong JY; Norris JS Cancer Gene Ther; 2005 Jan; 12(1):12-8. PubMed ID: 15514684 [TBL] [Abstract][Full Text] [Related]
5. Bladder cancer therapy using combined proliferating cell nuclear antigen antisense oligonucleotides and recombinant adenovirus p53. Zhu Z; Xing S; Lin C; Zhang X; Fu M; Liang X; Zeng F; Lu G; Wu M Chin Med J (Engl); 2003 Dec; 116(12):1860-3. PubMed ID: 14687474 [TBL] [Abstract][Full Text] [Related]
6. Dicoumarol potentiates cisplatin-induced apoptosis mediated by c-Jun N-terminal kinase in p53 wild-type urogenital cancer cell lines. Watanabe J; Nishiyama H; Matsui Y; Ito M; Kawanishi H; Kamoto T; Ogawa O Oncogene; 2006 Apr; 25(17):2500-8. PubMed ID: 16518417 [TBL] [Abstract][Full Text] [Related]
7. Human bladder cancer cells undergo cisplatin-induced apoptosis that is associated with p53-dependent and p53-independent responses. Konstantakou EG; Voutsinas GE; Karkoulis PK; Aravantinos G; Margaritis LH; Stravopodis DJ Int J Oncol; 2009 Aug; 35(2):401-16. PubMed ID: 19578756 [TBL] [Abstract][Full Text] [Related]
8. Vaccinia virus mediated p53 gene therapy for bladder cancer in an orthotopic murine model. Fodor I; Timiryasova T; Denes B; Yoshida J; Ruckle H; Lilly M J Urol; 2005 Feb; 173(2):604-9. PubMed ID: 15643273 [TBL] [Abstract][Full Text] [Related]
9. Additional gene therapy with rAAV-wt-p53 enhanced the efficacy of cisplatin in human bladder cancer cells. Ruifa H; Liwei L; Binxin L; Ximing L Urol Int; 2006; 77(4):355-61. PubMed ID: 17135787 [TBL] [Abstract][Full Text] [Related]
10. Growth inhibition efficacy of an adenovirus expressing dual therapeutic genes, wild-type p53, and anti-erbB2 ribozyme, against human bladder cancer cells. Irie A; Matsumoto K; Anderegg B; Kuruma H; Kashani-Sabet M; Scanlon KJ; Uchida T; Baba S Cancer Gene Ther; 2006 Mar; 13(3):298-305. PubMed ID: 16110311 [TBL] [Abstract][Full Text] [Related]
11. Aloe-emodin induces apoptosis in T24 human bladder cancer cells through the p53 dependent apoptotic pathway. Lin JG; Chen GW; Li TM; Chouh ST; Tan TW; Chung JG J Urol; 2006 Jan; 175(1):343-7. PubMed ID: 16406939 [TBL] [Abstract][Full Text] [Related]
12. Safety and growth suppressive effect of intra-hepatic arterial injection of AdCMV-p53 combined with CDDP to rat liver metastatic tumors. Okimoto T; Yahata H; Itou H; Shinozaki K; Tanji H; Sakaguchi T; Asahara T J Exp Clin Cancer Res; 2003 Sep; 22(3):399-406. PubMed ID: 14582698 [TBL] [Abstract][Full Text] [Related]
14. p51/p63, a novel p53 homologue, potentiates p53 activity and is a human cancer gene therapy candidate. Kunisaki R; Ikawa S; Maeda T; Nakazaki Y; Kurita R; Harata M; Shutoh Y; Bai YS; Soda Y; Tanabe T; Dohi T; Kato R; Ikawa Y; Asano S; Tani K J Gene Med; 2006 Sep; 8(9):1121-30. PubMed ID: 16832836 [TBL] [Abstract][Full Text] [Related]
15. Adenovirus-mediated gene therapy for bladder cancer: efficient gene delivery to normal and malignant human urothelial cells in vitro and ex vivo. Chester JD; Kennedy W; Hall GD; Selby PJ; Knowles MA Gene Ther; 2003 Jan; 10(2):172-9. PubMed ID: 12571646 [TBL] [Abstract][Full Text] [Related]
16. Midkine promoter-based conditionally replicative adenovirus for targeting midkine-expressing human bladder cancer model. Terao S; Shirakawa T; Kubo S; Bishunu A; Lee SJ; Goda K; Tsukuda M; Hamada K; Tagawa M; Takenaka A; Fujisawa M; Gotoh A Urology; 2007 Nov; 70(5):1009-13. PubMed ID: 17919690 [TBL] [Abstract][Full Text] [Related]
17. A protein transduction method using oligo-arginine (3R) for the delivery of transcription factors into cell nuclei. Hitsuda T; Michiue H; Kitamatsu M; Fujimura A; Wang F; Yamamoto T; Han XJ; Tazawa H; Uneda A; Ohmori I; Nishiki T; Tomizawa K; Matsui H Biomaterials; 2012 Jun; 33(18):4665-72. PubMed ID: 22465335 [TBL] [Abstract][Full Text] [Related]
18. [Effects of double targeting gene therapy by suicide gene combined with endostatin gene in treatment of bladder cancer: an experimental study]. Pan JG; Zhou X; Han RF Zhonghua Yi Xue Za Zhi; 2008 Oct; 88(38):2700-4. PubMed ID: 19080691 [TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibitor trichostatin A inhibits the growth of bladder cancer cells through induction of p21WAF1 and G1 cell cycle arrest. Li GC; Zhang X; Pan TJ; Chen Z; Ye ZQ Int J Urol; 2006 May; 13(5):581-6. PubMed ID: 16771729 [TBL] [Abstract][Full Text] [Related]
20. Effect of small interfering RNA targeting survivin gene on biological behaviour of bladder cancer. Hou JQ; He J; Wang XL; Wen DG; Chen ZX Chin Med J (Engl); 2006 Oct; 119(20):1734-9. PubMed ID: 17097022 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]